Dr. Shahid J. Siddiqui is a globally accomplished pharmaceutical and biotechnology executive whose career reflects more than three decades of leadership at the intersection of medical affairs, clinical development, regulatory strategy, and commercial execution. With experience spanning the United States, Europe, China, Japan, Latin America, Southeast Asia, and other emerging markets, he has built a reputation as a leader who combines scientific depth with enterprise vision. Throughout his career, he has consistently stepped into roles that required both operational discipline and strategic foresight, helping organizations navigate the complexities of drug development, launch readiness, evidence generation, and market expansion. His professional journey is defined by a rare ability to connect rigorous science with business priorities while keeping patients, innovation, and long-term value creation at the center of his work.
Based in Collegeville, Pennsylvania, Dr. Siddiqui has held senior leadership positions at some of the world’s most recognized pharmaceutical organizations, including GSK, Zambon USA, Regeneron, AstraZeneca, Forest Laboratories, Novartis, Chiron Corporation, and Eli Lilly. Across these institutions, he has led global and regional teams through pivotal moments of transformation, often building infrastructure where none existed before and strengthening functions that were essential to growth. His career progression reflects a steady expansion of scope and influence, from early medical and regulatory responsibilities to enterprise-level leadership over global portfolios, high-performing teams, and multi-million-dollar budgets. In every environment, from multinational corporations to emerging growth companies, he has been known as a leader who can quickly assess strategic needs, create alignment across functions, and deliver sustainable impact.
Much of Dr. Siddiqui’s recent leadership has centered on respiratory medicine, where he has played a significant role in advancing both pipeline and marketed assets. At GSK, he directed global medical strategy for the refractory chronic cough program, leading phase III analyses and shaping post-launch planning across the United States, Europe, China, and Japan. He established and scaled the global medical affairs function around this late-stage asset, recruited and developed talent, and built the scientific governance necessary to support evidence generation, external engagement, and launch preparedness. His stewardship of a substantial global budget underscored both the size of the opportunity and the trust placed in his leadership. More importantly, it highlighted his ability to create structure, momentum, and credibility around an emerging therapeutic area.
Before GSK, Dr. Siddiqui served as Vice President of U.S. Medical Affairs and Head of Operations at Zambon USA, where he was instrumental in building the U.S. rare disease affiliate and preparing it for market readiness. In that role, he brought together medical affairs, patient services, market access, and health economics strategy in a way that demonstrated his broader enterprise mindset. He helped define reimbursement and payer engagement approaches, built patient-centered support frameworks, and led scientific committee efforts that elevated the company’s standing in bronchiolitis obliterans syndrome. His work at Zambon reflected a defining strength of his career: the ability to translate medical strategy into practical infrastructure that supports commercialization, access, and long-term organizational growth.
At Regeneron, Dr. Siddiqui expanded his impact on a global scale by leading medical affairs strategy for important respiratory assets, including biologic programs in asthma and related inflammatory conditions. He oversaw a respiratory portfolio supported by a budget of approximately $65 million, while also leading a field-based medical organization and directing phase IIIb and IV studies, registries, and post-hoc evidence strategies. His role required close coordination across medical, commercial, development, and alliance teams, and he became a trusted contributor to integrated decision-making. His success in this environment reinforced his ability to manage complexity without losing sight of execution. Whether chairing advisory boards, reviewing statistical analysis plans, or aligning lifecycle strategies, he brought scientific rigor and strategic clarity to every level of the organization.
Dr. Siddiqui’s years at AstraZeneca further cemented his reputation as a leader capable of bridging clinical development and medical affairs. As a senior global medical affairs leader in respiratory, he supported major product launches, helped shape engagement strategies for medical science liaisons and key external experts, and led the design of important evidence-generation efforts in severe asthma and COPD. He served as clinical lead for major studies and played a central role in integrating medical initiatives with development and commercial priorities. Earlier, in a senior clinical development capacity within AstraZeneca’s respiratory organization, he led global programs in asthma and COPD, contributed to successful regulatory submissions, and helped drive an NDA approval. His experience negotiating regulatory pathways, overseeing safety, and aligning global teams around development milestones demonstrated both technical authority and organizational leadership.
Earlier chapters of his career show the breadth of his expertise and the foundation of his executive capabilities. At Forest Laboratories, he led phase IV development and medical affairs initiatives in COPD, while advancing regulatory strategy and preparing teams for interactions with health authorities. At Novartis, he helped standardize governance across respiratory clinical development through the creation of templates, steering structures, and oversight frameworks that improved consistency and execution. At MAP Pharmaceuticals and Aradigm, he directed respiratory development programs in pediatric asthma and cystic fibrosis, contributing to protocol design, regulatory planning, site strategy, and advisory board leadership. These experiences reflect a career built not only on senior titles, but on repeatedly solving difficult organizational and scientific problems.
Dr. Siddiqui’s international leadership is especially notable. During his time at Chiron Corporation, he established and expanded international medical affairs operations across Asia and Latin America, supporting programs in oncology and infectious disease while building key opinion leader networks in countries such as China, Korea, India, Singapore, Mexico, and South Africa. At Eli Lilly, where he held senior roles in Pakistan and Indonesia, he took on a uniquely broad scope that included medical leadership, clinical research, pharmacovigilance, regulatory activity, and even commercial oversight. He directed sizable teams, supported product registrations, launched oncology and endocrinology brands, and strengthened relationships with regulators and health authorities. This global experience gave him firsthand understanding of diverse healthcare systems, varied regulatory environments, and the local realities that shape successful execution across markets.
A defining hallmark of Dr. Siddiqui’s career is his ability to build and lead organizations. He has repeatedly been entrusted with creating medical affairs capabilities, recruiting talent, designing governance processes, and establishing systems that can scale from early development through post-launch optimization. He has led advisory boards and scientific committees across major global markets, developed KOL ecosystems across multiple therapeutic areas, and shaped evidence-generation strategies that support both regulatory and commercial success. His talent for building high-performing teams is matched by his commitment to mentoring people and fostering a culture of accountability, scientific excellence, and collaboration. In an industry where success often depends on how effectively functions work together, he has distinguished himself as a unifier who brings people around a shared vision.
His scientific and strategic influence is also reflected in a substantial body of publications, abstracts, and presentations. Dr. Siddiqui has contributed to peer-reviewed work in respiratory medicine, infectious disease, endocrinology, oncology, and related fields, with publications and presentations associated with respected journals and major scientific congresses such as ATS, ERS, ACAAI, and others. This sustained scholarly output demonstrates more than technical proficiency; it reflects his commitment to advancing evidence, shaping clinical dialogue, and ensuring that scientific insights are translated into practice. He has also served as an invited panelist and speaker, further underscoring his standing as a thought partner within the medical and scientific community.
Beyond his professional accomplishments, Dr. Siddiqui brings a perspective shaped by resilience, multicultural fluency, and a genuine desire to help organizations grow responsibly. Fluent in English and Hindi, and conversational in Bahasa, he has worked effectively across cultures and leadership contexts. He is motivated not simply by operational success, but by the opportunity to help companies build enduring franchises, sharpen development strategy, and bring meaningful therapies to patients worldwide. His stated interest in serving startups, biotechnology companies, pharmaceutical organizations, and investment-backed ventures reflects a forward-looking mindset: he sees board and executive leadership as a way to contribute his hard-earned experience to organizations at critical stages of growth and innovation.
For boards, executive committees, and leadership teams, Dr. Siddiqui offers an unusual combination of qualities. He is scientifically credible, commercially aware, operationally seasoned, and globally tested. He understands how to move from concept to clinic, from launch plan to market adoption, and from functional excellence to enterprise value creation. He has led through complexity, managed significant budgets, overseen regulatory and safety matters, and aligned stakeholders across medical, development, access, and commercial domains. That breadth makes him particularly well suited for organizations seeking a leader who can provide not only subject matter expertise, but also strategic judgment, governance maturity, and a calm, credible presence in the boardroom.
In sum, Dr. Shahid J. Siddiqui stands out as a distinguished global pharmaceutical executive whose career has been built on substance, scale, and sustained contribution. He has launched products, guided clinical programs, built organizations, strengthened scientific credibility, and supported growth across some of the most demanding and competitive areas of modern healthcare. His leadership reflects both intellectual range and practical discipline, making him a strong fit for board service, chief medical leadership, scientific advisory roles, and executive committee responsibilities. As industries continue to seek leaders who can bridge innovation with execution, and science with strategy, Dr. Siddiqui represents precisely that kind of trusted and transformative executive voice.
Character: Dr. Siddiqui is a principled leader whose career reflects consistency, integrity, and a deep sense of responsibility to patients, colleagues, and organizations. He has repeatedly taken on complex leadership challenges with steadiness and professionalism, earning trust across global teams and executive environments. His commitment to building ethical, high-performing organizations shows a leader guided not only by results, but by values.
Knowledge: Dr. Siddiqui brings exceptional knowledge across medical affairs, clinical development, regulatory strategy, pharmacovigilance, and commercialization. His expertise spans multiple therapeutic areas and global healthcare systems, enabling him to contribute with both depth and range. He understands the science, the evidence, the governance, and the business dynamics required to bring therapies successfully from development through launch and lifecycle optimization.
Strategic: Dr. Siddiqui is a strategic thinker who sees beyond immediate milestones to the broader architecture of growth, innovation, and competitive positioning. He has repeatedly aligned scientific priorities with market realities, payer dynamics, regulatory demands, and organizational capability building. His decisions are informed by both global perspective and practical execution, making him a valuable architect of long-term enterprise value.
Communication: Dr. Siddiqui is an effective and credible communicator who can engage equally well with scientists, regulators, commercial leaders, investors, and board members. He has demonstrated this through advisory boards, investigator meetings, regulatory interactions, publications, and executive leadership forums. His communication style combines clarity, authority, and diplomacy, helping organizations create alignment and momentum across diverse stakeholders.
